P
ProciseDx
Point-of-care testing that delivers precise, high-quality results
About ProciseDx
ProciseDx is a healthcare technology company specializing in point of care diagnostic solutions. The company operates in the medical diagnostics market, providing healthcare professionals with the ability to obtain lab-quality results in real-time, directly in their offices. ProciseDx's platform is optimized for quantitative immunoassays, which are tests that measure the presence or concentration of a substance in a solution using an antibody or antigen. This allows for immediate clinical decisions during patient appointments or pharmacy visits, significantly improving the efficiency of patient care.
The company's primary clients include gastroenterologists and other healthcare providers who require rapid and accurate diagnostic results to monitor therapeutic treatments, particularly for inflammatory bowel diseases. ProciseDx leverages proven technology and patented chemistry to deliver diagnostic answers from a finger prick sample in less than 5 minutes. This quick turnaround time enables healthcare professionals to make informed treatment decisions on the spot, enhancing patient outcomes.
ProciseDx's business model revolves around the sale of its diagnostic platform and assays, generating revenue through the sale of these products to healthcare providers. The company also benefits from recurring revenue through the continuous need for its diagnostic tests.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2005
- Headquarters
- San Diego, United States
- Employees
- 8
- Open positions
- None listed
- Dealroom signal
- 30.9/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Gastroenterology, Inflammatory Diseases, Health Diagnostics, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jun 2023 | $0 | — | Biosynex | ↗ |
| CONVERTIBLE✓Equity / VC | Jul 2021 | $13M | — | Undisclosed | — |
Growth signals
Latest recorded traffic for ProciseDx is 410 monthly website visits, down 70.7% over the last three months. ProciseDx's team declined 69.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Biosynex
Other known investors1 additional known investor
- BIBioBrit
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ProciseDx on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ProciseDx’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.